FURTHER EVALUATION OF THE PROGNOSTIC VALUE OF MORPHOMETRIC AND FLOW CYTOMETRIC PARAMETERS IN BREAST-CANCER PATIENTS WITH LONG FOLLOW-UP

被引:92
|
作者
UYTERLINDE, AM
BAAK, JPA
SCHIPPER, NW
PETERSE, H
MATZE, E
MEIJER, CJL
机构
[1] FREE UNIV AMSTERDAM HOSP,DEPT PATHOL,DE BOELELAAN 1117,1081 HV AMSTERDAM,NETHERLANDS
[2] ANTONI VAN LEEUWENHOEK HOSP,1066 CX AMSTERDAM,NETHERLANDS
关键词
D O I
10.1002/ijc.2910450102
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The added prognostic value of cellular DNA content compared with single and combined morphometric factors and classical parameters such as tumor size, nodal status, histologic grade and estrogen receptor (ER) content was investigated in 225 consecutive breast‐cancer patients with long follow‐up. Of all features investigated, the MPI (multivariate prognostic index) had the strongest prognostic value [Mantel‐Cox (MC) =48.2, p <0.00005]. The results further showed that neither age nor ER content had significant prognostic value, but the DNA index (DI) as a single parameter had (though weak) prognostic significance (MC =5.9, p =0.015); a similar result was obtained with the percentage of S‐phase cells (MC =6.1, p =0.013). The DI had (restricted) additional prognostic value to the morphometric features (MPI plus DI Mantel‐Cox 53.0, p <0.0001). The percentage of S‐phase cells had no additional prognostic value over the MPI. On the other hand, the additional value of the DI over tumor size and nodal status was much more impressive (MC =41.0 and 40.7), although it did not reach the prognostic significance of the MPI. Prediction of disease outcome with a linear combination of quantitative microscopical parameters of the primary tumor alone [MAI (mitotic activity index), DI and mean nuclear area] was very accurate, even without considering lymph‐node status (MC 30.8, p <0.0005). Grade had no additional value to the MPI at all (p =0.76). This could be especially important for lymph‐node‐negative patients in whom the prognostic value of the MPI and the MAI are confirmed. Copyright © 1990 Wiley‐Liss, Inc., A Wiley Company
引用
收藏
页码:1 / 7
页数:7
相关论文
共 50 条
  • [1] VALUE OF LABORATORY DIAGNOSIS IN FOLLOW-UP OF BREAST-CANCER PATIENTS
    SCHMIDTRHODE, P
    FRIEBE, M
    ZWIOREK, L
    SCHULZ, KD
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 1993, 254 (1-4) : 814 - 816
  • [2] FOLLOW-UP OF PATIENTS WITH BREAST-CANCER
    PACE, BW
    TINKER, MA
    CLINICAL OBSTETRICS AND GYNECOLOGY, 1994, 37 (04): : 998 - 1002
  • [3] FOLLOW-UP OF BREAST-CANCER PATIENTS
    KINDLER, M
    STEINHOFF, G
    ONCOLOGY, 1989, 46 (06) : 360 - 365
  • [4] FOLLOW-UP OF BREAST-CANCER PATIENTS
    HORTON, J
    CANCER, 1984, 53 (03) : 790 - 797
  • [5] FOLLOW-UP IN BREAST-CANCER - PATIENTS PREFER SPECIALIST FOLLOW-UP
    MAHER, J
    BRADBURN, J
    ADEWUYIDALTON, R
    BRITISH MEDICAL JOURNAL, 1995, 311 (6996): : 54 - 54
  • [6] THE ROLE OF CARCINOEMBRYONIC ANTIGEN IN THE POSTMASTECTOMY FOLLOW-UP OF PRIMARY BREAST-CANCER AND IN THE PROGNOSTIC EVALUATION OF DISSEMINATED BREAST-CANCER
    PALAZZO, S
    LIGUORI, V
    MOLINARI, B
    GRECO, LM
    MANCINI, V
    TUMORI, 1984, 70 (01) : 57 - 59
  • [7] FOLLOW-UP OF PATIENTS WITH BREAST-CANCER - REPLY
    FOSSATI, R
    LIBERATI, A
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 272 (21): : 1658 - 1659
  • [8] STAGING AND FOLLOW-UP OF BREAST-CANCER PATIENTS
    KINNE, DW
    CANCER, 1991, 67 (04) : 1196 - 1198
  • [9] PROGNOSTIC VALUE OF PROGESTERONE-RECEPTOR AFTER LONG-TERM FOLLOW-UP IN PRIMARY BREAST-CANCER
    PICHON, MF
    PALLUD, C
    HACENE, K
    MILGROM, E
    EUROPEAN JOURNAL OF CANCER, 1992, 28A (10) : 1676 - 1680
  • [10] FOLLOW-UP IN BREAST-CANCER
    DEWAR, J
    BMJ-BRITISH MEDICAL JOURNAL, 1995, 310 (6981): : 685 - 686